Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by stock analysts at Canaccord Genuity from $390.00 to $410.00 in a research note issued to investors on Thursday, Stock Target Advisor reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price target suggests a potential upside of 6.73% from the stock’s current price.

REGN has been the subject of several other reports. ValuEngine raised Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 6th. BidaskClub raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 1st. Argus raised their price objective on Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Leerink Swann raised their price objective on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a research note on Monday, October 1st. Finally, UBS Group raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Wednesday, June 27th. Two equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $412.19.

REGN opened at $384.16 on Thursday. The company has a quick ratio of 2.92, a current ratio of 3.62 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $43.66 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 1.35 and a beta of 1.12. Regeneron Pharmaceuticals has a 12 month low of $281.89 and a 12 month high of $453.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, beating the consensus estimate of $4.60 by $0.85. The business had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm earned $4.17 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 19.4 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the transaction, the director now owns 1,500 shares of the company’s stock, valued at $570,735. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael S. Brown sold 2,000 shares of the firm’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total value of $784,520.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $784,520. The disclosure for this sale can be found here. Insiders have sold 112,052 shares of company stock valued at $45,411,762 in the last three months. 12.42% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Intl Fcstone Inc. purchased a new position in Regeneron Pharmaceuticals during the second quarter worth $233,000. Raymond James & Associates increased its position in Regeneron Pharmaceuticals by 57.4% during the second quarter. Raymond James & Associates now owns 81,916 shares of the biopharmaceutical company’s stock worth $28,260,000 after buying an additional 29,864 shares in the last quarter. Founders Capital Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $226,000. Signaturefd LLC grew its position in shares of Regeneron Pharmaceuticals by 123.8% in the second quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 198 shares during the period. Finally, First Trust Advisors LP grew its position in shares of Regeneron Pharmaceuticals by 26.9% in the second quarter. First Trust Advisors LP now owns 187,988 shares of the biopharmaceutical company’s stock valued at $64,854,000 after purchasing an additional 39,879 shares during the period. 66.90% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: 52-Week High/Low Prices For Stock Selection

Stock Target Advisor

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.